Skip to main content
VYNE Therapeutics Inc. logo

VYNE Therapeutics Inc. — Investor Relations & Filings

Ticker · VYNE ISIN · US92941V1008 US Manufacturing
Open in API
Filings indexed 608 across all filing types
Latest filing 2020-03-03 Regulatory Filings
Country US United States of America
Listing US VYNE

About VYNE Therapeutics Inc.

https://vynetherapeutics.com/

VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions. The company's primary objective is to address unmet medical needs by advancing a pipeline of novel drug candidates. VYNE's approach centers on innovating beyond traditional assumptions to find improved solutions for patients with complex inflammatory and immunological diseases.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated March 3, 2020, by Menlo Therapeutics Inc. It announces the issuance of a press release with financial results for the quarter and year ended December 31, 2019. The text explicitly states that the press release is furnished as an exhibit and that the information is not deemed "filed" for certain regulatory purposes. The document itself is short (3559 characters) and primarily serves as an announcement of the earnings release rather than containing the financial results or detailed analysis itself. According to the rules, such a document is classified as an Earnings Release (ER) if it contains key highlights only, but since this is a Form 8-K announcing the press release and not the press release text itself, it fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement and does not contain the full earnings content. Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2020-03-03 English
Major Shareholding Notification 2020
Major Shareholding Notification
2020-02-14 English
JANUS HENDERSON GROUP PLC OWNS 5.3% OF MENLO
Major Shareholding Notification
2020-02-13 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated February 6, 2020, reporting the submission of matters to a vote of security holders at a special meeting related to a merger agreement. It includes detailed voting results on merger proposals and references a joint proxy statement filed earlier. The content focuses on shareholder voting results and merger-related approvals, which aligns with the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document is over 11,000 characters, contains substantive information about the vote, and is not merely an announcement of a report or a proxy solicitation. Therefore, the appropriate classification is DVA with high confidence.
2020-02-06 English
425 Filing
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated February 6, 2020, reporting the submission of matters to a vote of security holders at a special meeting related to a merger agreement. It details the voting results on merger proposals and includes a press release about stockholder approval. The content focuses on the official results of shareholder votes at a general meeting. This matches the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA). The document is over 11,000 characters, so it is not a mere announcement of a report but the actual voting results. Therefore, the correct classification is DVA with high confidence.
2020-02-06 English
NONE
Major Shareholding Notification
2020-02-04 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.